BioCentury | Dec 16, 1996
Finance

Early (or late?) to the starting gate

...developer Biosite Diagnostics; Coulter Pharmaceutical, a developer of lymphoma therapies; and Epix Medical Inc. (formerly Metasyn...
BioCentury | Nov 25, 1996
Company News

Metasyn diagnostics/imaging news

...a contrast imaging agent designed for use with magnetic resonance imaging to diagnose cardiovascular disease. Metasyn Inc....
BioCentury | Oct 21, 1996
Clinical News

MS-325 injectable contrast agent for MRI: Metasyn's agent is in Phase I testing in healthy volunteers.

...Cambridge, Mass. Product: MS-325 injectable contrast agent for MRI Indication: Image blood vessels Status: Metasyn's...
BioCentury | Oct 7, 1996
Company News

Metasyn, Mallinckrodt Group Inc. deal

...develop and market MS-325 , Metasyn's agent for imaging cardiovascular systems in magnetic resonance imaging. Metasyn...
...The companies will share development costs. Mallinckrodt is responsible for product marketing worldwide, excluding Japan. Metasyn Inc....
BioCentury | Aug 12, 1996
Emerging Company Profile

Metasyn Inc.

Metasyn Inc. Cambridge, Mass. Technology: MRI contrast agents Disease focus: Cardiovascular and neurological imaging Clinical status: Preclinical Founded: 1992 by Randall Lauffer,former director of the NMR Contrast Media Laboratory at Massachusetts General Hospital and assistant...
BioCentury | Aug 12, 1996
Emerging Company Profile

Metasyn: Declaring revolution in MRI

...nature of magnetic resonance imaging and ultrasound imaging make them highly appealing as diagnostic modalities. Metasyn Inc....
...in the past few years, driven by improvements in both software and hardware, according to Metasyn...
...what used to be a multimillion-dollar investment is now in the range of $750,000-$1 million. Metasyn's...
BioCentury | Jun 17, 1996
Finance

Wow, 1-4

...Kogyo will buy an additional $2.5 million of shares at the offering price. PRIVATE ROUNDS: Metasyn Inc....
...the company determine when to pursue an IPO, according to President and CEO Michael Webb. Metasyn...
BioCentury | Apr 22, 1996
Clinical News

Metasyn regulatory update

...METASYN said Massachusetts General Hospital received notices of allowance for patents in Europe and Japan. METASYN...
...complexes to enhance the blood and/or liver on MRI scans and increase their signal-generating efficiency. METASYN...
...used in conjunction with MRI to produce images of blood vessels throughout the cardiovascular system. METASYN Inc....
BioCentury | Apr 15, 1996
Company News

Metasyn, Daicchi Radioisotope Laboratories Ltd. deal

...The companies entered into an agreement in Japan for MS-325 , METASYN's vascular enhancement agent for...
...enhancement agent for magnetic resonance imaging. Daiichi is responsible for clinical development, registration and commercialization. METASYN...
...METASYN retains rights to MS-325 outside of Japan, and will manufacture the product for Daiichi. METASYN Inc....
BioCentury | Oct 10, 1994
Company News

Metasyn other research news

...MRI agent with increased sensitivity and the potential to distinguish benign tumors from malignant tumors. Metasyn...
...agents, MS-136, led to significant signal enhancement in a rat model of malignant breast tumors. Metasyn Inc....
Items per page:
1 - 10 of 11
BioCentury | Dec 16, 1996
Finance

Early (or late?) to the starting gate

...developer Biosite Diagnostics; Coulter Pharmaceutical, a developer of lymphoma therapies; and Epix Medical Inc. (formerly Metasyn...
BioCentury | Nov 25, 1996
Company News

Metasyn diagnostics/imaging news

...a contrast imaging agent designed for use with magnetic resonance imaging to diagnose cardiovascular disease. Metasyn Inc....
BioCentury | Oct 21, 1996
Clinical News

MS-325 injectable contrast agent for MRI: Metasyn's agent is in Phase I testing in healthy volunteers.

...Cambridge, Mass. Product: MS-325 injectable contrast agent for MRI Indication: Image blood vessels Status: Metasyn's...
BioCentury | Oct 7, 1996
Company News

Metasyn, Mallinckrodt Group Inc. deal

...develop and market MS-325 , Metasyn's agent for imaging cardiovascular systems in magnetic resonance imaging. Metasyn...
...The companies will share development costs. Mallinckrodt is responsible for product marketing worldwide, excluding Japan. Metasyn Inc....
BioCentury | Aug 12, 1996
Emerging Company Profile

Metasyn Inc.

Metasyn Inc. Cambridge, Mass. Technology: MRI contrast agents Disease focus: Cardiovascular and neurological imaging Clinical status: Preclinical Founded: 1992 by Randall Lauffer,former director of the NMR Contrast Media Laboratory at Massachusetts General Hospital and assistant...
BioCentury | Aug 12, 1996
Emerging Company Profile

Metasyn: Declaring revolution in MRI

...nature of magnetic resonance imaging and ultrasound imaging make them highly appealing as diagnostic modalities. Metasyn Inc....
...in the past few years, driven by improvements in both software and hardware, according to Metasyn...
...what used to be a multimillion-dollar investment is now in the range of $750,000-$1 million. Metasyn's...
BioCentury | Jun 17, 1996
Finance

Wow, 1-4

...Kogyo will buy an additional $2.5 million of shares at the offering price. PRIVATE ROUNDS: Metasyn Inc....
...the company determine when to pursue an IPO, according to President and CEO Michael Webb. Metasyn...
BioCentury | Apr 22, 1996
Clinical News

Metasyn regulatory update

...METASYN said Massachusetts General Hospital received notices of allowance for patents in Europe and Japan. METASYN...
...complexes to enhance the blood and/or liver on MRI scans and increase their signal-generating efficiency. METASYN...
...used in conjunction with MRI to produce images of blood vessels throughout the cardiovascular system. METASYN Inc....
BioCentury | Apr 15, 1996
Company News

Metasyn, Daicchi Radioisotope Laboratories Ltd. deal

...The companies entered into an agreement in Japan for MS-325 , METASYN's vascular enhancement agent for...
...enhancement agent for magnetic resonance imaging. Daiichi is responsible for clinical development, registration and commercialization. METASYN...
...METASYN retains rights to MS-325 outside of Japan, and will manufacture the product for Daiichi. METASYN Inc....
BioCentury | Oct 10, 1994
Company News

Metasyn other research news

...MRI agent with increased sensitivity and the potential to distinguish benign tumors from malignant tumors. Metasyn...
...agents, MS-136, led to significant signal enhancement in a rat model of malignant breast tumors. Metasyn Inc....
Items per page:
1 - 10 of 11